EDAP Announces Final Results from HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy to be Presented During Plenary Session at the Upcoming 119th American Urological Association (AUA) Annual MeetingGlobeNewsWire • Tuesday
EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024GlobeNewsWire • 03/13/24
EDAP to Present at the Oppenheimer 34th Annual Healthcare MedTech & Services ConferenceGlobeNewsWire • 03/06/24
EDAP Announces FDA Breakthrough Device Designation for Focal One® in the Treatment of Deep Infiltrating Rectal EndometriosisGlobeNewsWire • 03/04/24
EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and PlacementsGlobeNewsWire • 01/08/24
EDAP Appoints Ken Mobeck, Global Chief Financial Officer, and Francois Dietsch, Global Chief Accounting OfficerGlobeNewsWire • 01/02/24
EDAP Announces Positive Opinion for Reimbursement from the French National Authority for Health (HAS) for HIFU treatment of Prostate CancerGlobeNewsWire • 12/12/23
EDAP Receives 2023 Industry Category Award from the French National Institute for Intellectual Property (INPI) for Its Therapeutic Ultrasound TechnologyGlobeNewsWire • 11/30/23
EDAP: Expecting Commercial Success In Prostate Cancer With Pipeline ExpansionSeeking Alpha • 10/27/23
EDAP TMS SA to Announce Third Quarter 2023 Financial Results on November 9, 2023GlobeNewsWire • 10/26/23
EDAP to Present at Morgan Stanley Annual Global Healthcare Conference and the H.C. Wainwright Annual Global Investment ConferenceGlobeNewsWire • 09/06/23
EDAP TMS SA to Announce Second Quarter 2023 Financial Results on August 24, 2023GlobeNewsWire • 08/10/23
EDAP Announces Reimbursement Approval in Switzerland for the Use of High-Intensity Focused Ultrasound (HIFU) in the Treatment of Prostate CancerGlobeNewsWire • 07/26/23